drugset / Trial / NCT06864507

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HS-10561 Capsule in Healthy Chinese Adults and Patients With Chronic Spontaneous Urticaria.

NCT06864507 ↗

Phase 1/2 Not yet recruiting 150 enrolled Jiangsu Hansoh Pharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a randomized, double-blind, placebo-controlled phase 1/2 clinical study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of HS-10561 capsule in healthy Chinese adults and patients with chronic spontaneous urticaria.

Timeline

Start
2025-03-31
Primary completion
2026-09-27
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject HS-10561 Unknown — Oral